Please assess the completion status of the following clinical trial:

Trial Title: Role of Exenatide in Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~\*\*\*Subjects must be patients of the Texas Children's Hospital Diabetes Care Center\*\*\*.~All of the following criteria must be met:~1. Between 12-21 years of age at the time of enrollment.~2. Have been diagnosed with Type 1 diabetes for at least 1 year and in good control (HbA1C less than 8.5%).~3. Subjects must be otherwise healthy except for the Type 1 Diabetes and treated hypothyroidism.~4. Menstruating women must have a negative pregnancy test.~5. Hemoglobin equal to or greater than 12 g/dL before each study.~6. Weight greater than 44 kg.~7. Tanner stage greater than 3~Exclusion Criteria:~1. Any chronic disease: leukemia, asthma, inflammatory bowel disease, cystic fibrosis, juvenile rheumatoid arthritis etc or on treatment that might directly or indirectly affect glucose homeostasis, except for diabetes and hypothyroidism; stable on medications.~2. Lack of a supportive family environment as detected by the clinicians and/or social workers.~3. Positive pregnancy test in menstruating young women.~4. BMI greater than 90th percentile for age or less than 10th percentile for age.~5. Lactating and nursing mothers.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide 1.25 mcg + Insulin (Type: EXPERIMENTAL): In each intervention arm the participant receives a different dose of Exenatide along with Insulin as a single subcutaneous injection
- Exenatide 2.5 mcg + Insulin (Type: EXPERIMENTAL): In each intervention arm the participant receives a different dose of Exenatide along with Insulin as a single subcutaneous injection
- Insulin (Type: ACTIVE_COMPARATOR): Each subject received a baseline study with insulin alone

Based on this trial design, predict the completion outcome and termination type (if applicable).